Citations

Clear

153 citation(s) found for "Gleich, GJ".

Association between Exposure of Young Children to Procedures Requiring General Anesthesia and Learning and Behavioral Outcomes in a Population-based Birth Cohort
Hu, Danqing , Flick, Randall P., Zaccariello, Michael J. , Colligan, Robert C., Katusic, Slavica K., Schroeder, Darrell R. , Hanson, Andrew C. , Buenvenida, Shonie L., Gleich, Stephen J. , Wilder, Robert T. , Šprung, Juraj , Warner, David O. , Schroeder, Darrell

Mayo Clinic

Anesthesiology | June 13, 2017 | Volume: 127 | Issue: 2 | Pages: 227-240

10.1097/aln.0000000000001735 | PMID 28609302 Get It

Abstract Background Exposure of young animals to general anesthesia causes neurodegeneration and lasting behavioral abnormalities; whether these findings translate to children remains unclear. This study used a population-based birth cohort to test the hypothesis that multiple, but not single, exposures to procedures requiring general anesthesia before age 3 yr are associated with adverse neurodevelopmental outcomes. Methods A retrospective study cohort was assembled from children born in Olmsted County, Minnesota, from 1996 to 2000 (inclusive). Propensity matching selected children exposed and not exposed to general anesthesia before age 3 yr. Outcomes ascertained via medical and school records included learning disabilities, attention-deficit/hyperactivity disorder, and group-administered ability and achievement tests. Analysis methods included proportional hazard regression models and mixed linear models. Results For the 116 multiply exposed, 457 singly exposed, and 463 unexposed children analyzed, multiple, but not single, exposures were associated with an increased frequency of both learning disabilities and attention-deficit/hyperactivity disorder (hazard ratio for learning disabilities = 2.17 [95% CI, 1.32 to 3.59], unexposed as reference). Multiple exposures were associated with decreases in both cognitive ability and academic achievement. Single exposures were associated with modest decreases in reading and language achievement but not cognitive ability. Conclusions These findings in children anesthetized with modern techniques largely confirm those found in an older birth cohort and provide additional evidence that children with multiple exposures are more likely to develop adverse outcomes related to learning and attention. Although a robust association was observed, these data do not determine whether anesthesia per se is causal.
Comparative Toxicity of Purified Human Eosinophil Granule Cationic Proteins for Schistosomula of Schistosoma Mansoni *
Ackerman, Steven J. , Gleich, Gerald J. , Butterworth, A , Loegering, David A., Richardson, Brian A.

Mayo Clinic

The American Journal of Tropical Medicine and Hygiene | May 10, 2017 | Volume: 34 | Issue: 4 | Pages: 735-745

10.4269/ajtmh.1985.34.735 | PMID 4025686 Get It

Anesthetic Outcomes of Children With Arthrogryposis Syndromes: No Evidence of Hyperthermia
Gleich, Stephen J. , Tien, Michael , Schroeder, Darrell R. , Hanson, Andrew C. , Flick, Randall P., Nemergut, Michael E. , Schroeder, Darrell

Mayo Clinic

Anesthesia & Analgesia | January 17, 2017 | Volume: 124 | Issue: 3 | Pages: 908-914

10.1213/ane.0000000000001822 | PMID 28099287 Get It

BACKGROUND: Arthrogryposis syndromes are a heterogeneous group of disorders characterized by congenital joint contractures often requiring multiple surgeries during childhood to address skeletal and visceral abnormalities. Previous reports suggest that these children have increased perioperative risk, including hypermetabolic events discrete from malignant hyperthermia, difficult airway management, isolated hyperthermia, and difficult IV line placement. We sought to compare children with arthrogryposis multiplex congenita (AMC) versus the less severe, distal arthrogryposis syndromes (DAS) and to evaluate possible intraoperative hyperthermia of patients with AMC. We hypothesized that children with AMC had a greater incidence of intraoperative hyperthermia and more difficulty with airway management and IV access. METHODS: Children aged 0 to 25 years with arthrogryposis syndromes who underwent anesthesia from 1972 to 2013 were identified. The medical records were reviewed for demographics, arthrogryposis type, and anesthetic complications. AMC subjects were compared with DAS subjects. To evaluate the probability of hyperthermia and hypermetabolic responses of patients with AMC, we performed a post hoc case–control analysis. Patients with AMC were matched in a 1:2 ratio to patients without arthrogryposis to evaluate the primary outcome of maximum intraoperative temperature. RESULTS: Forty-five patients with AMC and 16 patients with DAS underwent 264 and 105 unique anesthetics, respectively. There was no significant difference in intraoperative hyperthermia or hypermetabolic events (odds ratio [OR], 0.94; 95% confidence interval [CI], 0.36–2.47; P = .90). Children with AMC were more likely to have difficult IV access (OR, 7.1; 95% CI, 1.81–27.90; P = .005). Additional evidence suggested that difficult airway management (OR, 4.06; 95% CI, 1.01–16.39; P = .049) and hemodynamic instability (OR, 4.22; 95% CI, 1.03–17.26; P = .045) were more likely in children with AMC. From post hoc case–control analysis, there was no significant difference in the mean maximum intraoperative temperature (estimated difference +0.04°C; 95% CI, −0.14 to +0.22; P = .64) or odds of intraoperative hyperthermia (OR, 1.49; 95% CI, 0.78–2.82; P = .223) for patients with AMC compared with control subjects. CONCLUSIONS: Children with arthrogryposis syndromes present challenges to the anesthesia and surgical teams, including greater neuromuscular disease burden and challenging peripheral IV placement, with additional evidence suggesting difficult airway management and intraoperative hemodynamic instability. Although more definitive studies are warranted, we did not find evidence of increased odds of intraoperative hyperthermia or hypermetabolic responses.
Procedure for difficult peripheral intravenous access in children with chronic health conditions
Gleich, Stephen J. , Nemergut, Michael E.

Mayo Clinic

Pediatric Anesthesia | September 7, 2016 | Volume: 26 | Issue: 10 | Pages: 1026-1027

10.1111/pan.12970 | PMID 27600757 Get It

Improvement in Patient Transfer Process From the Operating Room to the PICU Using a Lean and Six Sigma–Based Quality Improvement Project
Gleich, Stephen J. , Stans, Anthony A. , Haile, Dawit T. , Feigal, Scott A., Heinrich, Angela L., Bosley, Christopher, Nemergut, Michael E. , Feigal, Scott A., Heinrich, Angela L., Tripathi, Sandeep

Mayo Clinic

Hospital Pediatrics | August 1, 2016 | Volume: 6 | Issue: 8 | Pages: 483-489

10.1542/hpeds.2015-0232 | PMID 27471214 Get It

BACKGROUND AND OBJECTIVES: Ineffective and inefficient patient transfer processes can increase the chance of medical errors. Improvements in such processes are high-priority local institutional and national patient safety goals. At our institution, nonintubated postoperative pediatric patients are first admitted to the postanesthesia care unit before transfer to the PICU. This quality improvement project was designed to improve the patient transfer process from the operating room (OR) to the PICU. METHODS: After direct observation of the baseline process, we introduced a structured, direct OR-PICU transfer process for orthopedic spinal fusion patients. We performed value stream mapping of the process to determine error-prone and inefficient areas. We evaluated primary outcome measures of handoff error reduction and the overall efficiency of patient transfer process time. Staff satisfaction was evaluated as a counterbalance measure. RESULTS: With the introduction of the new direct OR-PICU patient transfer process, the handoff communication error rate improved from 1.9 to 0.3 errors per patient handoff (P = .002). Inefficiency (patient wait time and non–value-creating activity) was reduced from 90 to 32 minutes. Handoff content was improved with fewer information omissions (P < .001). Staff satisfaction significantly improved among nearly all PICU providers. CONCLUSIONS: By using quality improvement methodology to design and implement a new direct OR-PICU transfer process with a structured multidisciplinary verbal handoff, we achieved sustained improvements in patient safety and efficiency. Handoff communication was enhanced, with fewer errors and content omissions. The new process improved efficiency, with high staff satisfaction.
An automated real‐time method for the detection of patients at risk for malignant hyperthermia
Gleich, Stephen J. , Strupp, Kim M. , Wilder, Robert T., Kor, Daryl J. , Flick, Randall P., Flick, Randall

Mayo Clinic

Pediatric Anesthesia | June 27, 2016 | Volume: 26 | Issue: 9 | Pages: 876-882

10.1111/pan.12954 | PMID 27346873 Get It

SummaryBackgroundMalignant hyperthermia (MH) is a rare anesthetic pharmacogenetic disorder that can be difficult to detect in its earliest phases. Prompt treatment is known to improve outcomes. The modern anesthesia information management systems (AIMS) collect enormous amounts of data. However, data lack context and are not able to provide real‐time guidance. Utilizing our AIMS, we developed the capacity to incorporate decision support.AimsWe describe the creation and evaluation of a real‐time detection tool for MH.MethodsCases of MH from 2003 to 2013 were retrospectively reviewed to confirm the diagnosis of MH and to calculate a MH clinical grading scale score. The index cases were utilized to develop four electronic data Rules, based on endtidal CO2 (ETCO2) and temperature criteria. The Rules were then applied retrospectively to the index cases and to a full cohort of general operating room (OR) patients from January 2012 to June 2012. If criteria for possible MH was met, the detection tool generated an alert on the monitor at the patient's bedside.ResultsWe identified seven patients with confirmed MH with MH Scores ranging from 28 to 70. Using four data Rules, all of our seven index cases were captured and generated an appropriate alert. Median time from MH computer alert time to dantrolene administration time among our index cases was 23 min (IQR 17–77). There were 938 false‐positive alerts for possible MH (1.8%) when the Rules were applied to a general OR cohort of 51 579 total cases from January 2012 to June 2012.ConclusionsWe demonstrated a real‐time MH detection tool based on established physiologic criteria that is sensitive enough to capture cases suspicious for MH, while limiting false positives to prevent alarm fatigue. This has the potential to notify the provider of possible MH such that treatment may be rapidly initiated.
An immunologic test for chronic rhinosinusitis based on free intranasal eosinophilic major basic protein
Ponikau, Jens U., Winter, Laurie A., Kephart, Gail M., Squillace, Diane L., Hershcovitch, Matt D., Moon, Seo, Sherris, David A., Kern, Eugene B. , Gleich, Gerald J. , Kita, Hirohito , Kita, H

Mayo Clinic

International Forum of Allergy & Rhinology | September 29, 2014 | Volume: 5 | Issue: 1 | Pages: 28-35

10.1002/alr.21421 | PMID 25266917 Get It

BackgroundA histologic hallmark of chronic rhinosinusitis (CRS) is an eosinophilic inflammation, present with and without nasal polyposis and independent of atopy. Eosinophils migrate through nasal tissue including the epithelium into the nasal airway mucus, where they form clusters and degranulate, releasing granule proteins including the toxic major basic protein (MBP). Specific biomarkers for CRS, which could be used as a diagnostic test for CRS with a high sensitivity and specificity, are presently lacking. Recently, an enzyme‐linked immunosorbent assay (ELISA)‐based test for MBP in nasal airway mucus received regulatory approval.MethodsA new assay was specifically developed to detect released MBP in airway mucus. MBP levels in nasal mucus of 85 randomly selected CRS patients diagnosed by endoscopy, computed tomography (CT) scans and symptoms were compared to 13 healthy controls and 5 disease controls (allergic rhinitis).ResultsOverall, 92% (78/85) of CRS patients’ mucus were positive for MBP (mean 7722 ng/mL) vs none of 13 healthy controls and none of 5 allergic rhinitis patients (<7.8 ng/mL; p < 0.000000000002). In this study, the MBP ELISA had a 92% sensitivity and 100% specificity for CRS.ConclusionFree MBP in nasal mucus can be used as a biomarker to diagnose CRS. The MBP ELISA represents the first immunologically‐based test to potentially distinguish CRS from the eosinophilic inflammation in allergic rhinitis.
Extensive Eosinophil Degranulation and Peroxidase-Mediated Oxidation of Airway Proteins Do Not Occur in a Mouse Ovalbumin-Challenge Model of Pulmonary Inflammation
Denzler, Karen L., Borchers, Michael T. , Crosby, Jeffrey R., Cieslewicz, Grzegorz, Hines, Edith M., Justice, J. Paul, Cormier, Stephania A. , Lindenberger, Kari A., Song, Wei , Wu, Weijia , Hazen, Stanley L. , Gleich, Gerald J. , Lee, James J. , Lee, Nancy A.

Mayo Clinic

The Journal of Immunology | April 21, 2014 | Volume: 167 | Issue: 3 | Pages: 1672-1682

10.4049/jimmunol.167.3.1672 | PMID 11466391 Get It

Abstract Paradigms of eosinophil effector function in the lungs of asthma patients invariably depend on activities mediated by cationic proteins released from secondary granules during a process collectively referred to as degranulation. In this study, we generated knockout mice deficient for eosinophil peroxidase (EPO) to assess the role(s) of this abundant secondary granule protein in an OVA-challenge model. The loss of EPO had no effect on the development of OVA-induced pathologies in the mouse. The absence of phenotypic consequences in these knockout animals extended beyond pulmonary histopathologies and airway changes, as EPO-deficient animals also displayed OVA-induced airway hyperresponsiveness after provocation with methacholine. In addition, EPO-mediated oxidative damage of proteins (e.g., bromination of tyrosine residues) recovered in bronchoalveolar lavage from OVA-treated wild-type mice was &lt;10% of the levels observed in bronchoalveolar lavage recovered from asthma patients. These data demonstrate that EPO activities are inconsequential to the development of allergic pulmonary pathologies in the mouse and suggest that degranulation of eosinophils recruited to the lung in this model does not occur at levels comparable to those observed in humans with asthma.
Biological Activities of Ecalectin: A Novel Eosinophil-Activating Factor
Matsumoto, Ryoji, Hirashima, Mitsuomi , Kita, Hirohito , Gleich, Gerald J. , Kita, H

Mayo Clinic

The Journal of Immunology | April 20, 2014 | Volume: 168 | Issue: 4 | Pages: 1961-1967

10.4049/jimmunol.168.4.1961 | PMID 11823532 Get It

Abstract Ecalectin, produced by Ag-stimulated T lymphocytes, is a potent eosinophil-specific chemoattractant in vitro as well as in vivo and thus is implicated in allergic responses. Ecalectin differs structurally from other known eosinophil chemoattractants (ECAs); ecalectin belongs to the galectin family defined by their affinity for β-galactosides and by their conserved carbohydrate recognition domains. These characteristic features suggest that ecalectin has unique activities associated with allergic inflammation besides ECA activity. Conversely, ecalectin may mediate ECA activity by binding to a receptor of a known ECA via affinity for the β-galactosides present on this receptor. In this study, we have tested whether ecalectin mediates ECA activity by binding to a receptor of a known ECA, and we have assessed its effects on eosinophils. Ecalectin did not mediate ECA activity by binding to the IL-5R or to CCR3. Also, the ECA activity of ecalectin was mainly chemokinetic. In addition, ecalectin induced concentration-dependent eosinophil aggregation, a marker for eosinophil activation. Ecalectin induced concentration-dependent superoxide production from eosinophils but did not induce degranulation; usually these two events are coupled in eosinophil activation. Moreover, ecalectin directly prolonged eosinophil survival in vitro and did not trigger eosinophils to secrete cytokines that prolong eosinophil survival. These results demonstrate that ecalectin has several unique effects on eosinophils. Therefore, we conclude that ecalectin is a novel eosinophil-activating factor. Presumably, these effects allow ecalectin to play a distinctive role in allergic inflammation.
Major Basic Protein Homolog (MBP2): A Specific Human Eosinophil Marker
Plager, Douglas A., Loegering, David A., Checkel, James L., Tang, Junger, Kephart, Gail M., Caffes, Patricia L., Adolphson, Cheryl R., Ohnuki, Lyo E., Gleich, Gerald J.

Mayo Clinic

The Journal of Immunology | April 18, 2014 | Volume: 177 | Issue: 10 | Pages: 7340-7345

10.4049/jimmunol.177.10.7340 | PMID 17082653 Get It

Abstract Human eosinophil granule major basic protein (MBP1) is an exceedingly basic (isoelectric point &gt;11) 14-kDa protein, comprising the core of the secondary eosinophil granule. Recently, a less cationic homolog of MBP, termed MBPH or simply, MBP2, has been discovered. We prepared a panel of mAbs to MBP2 and used these Abs to localize and quantitate this molecule in leukocytes and biological fluids. Specific mAbs for MBP2 were selected using slot-blot analyses and used in a two-site immunoassay, Western blotting, and immunofluorescence microscopy. The sensitivity of the immunoassay was markedly improved by reduction and alkylation of MBP2. MBP1 is more abundant than MBP2 in lysates of eosinophils and their granules, as judged by immunoassay and Western blotting. By immunofluorescence, MBP1 is present in eosinophils, basophils, and a human mast cell line (HMC1), whereas MBP2 is only detected in eosinophils. Neither MBP1 nor MBP2 could be detected in any other peripheral blood leukocyte. MBP2 levels measured in plasma and serum were essentially identical. In contrast to past measurements for MBP1, MBP2 was not detected above normal levels in sera from pregnant donors. However, measurement of serum MBP2 discriminated patients with elevated eosinophils from normal subjects, and MBP2 was also detectable in other biological specimens, such as bronchoalveolar lavage, sputum, and stool. These results indicate that MBP2 is present only in eosinophils and that it may be a useful biomarker for eosinophil-associated diseases.